News

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

As a medical student at the University of Miami Miller School of Medicine, Ashlyn Anzu Gary landed the unique opportunity to help launch an interdisciplinary clinical research program exploring hypnotherapy as a treatment for people with chronic eye pain.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

According to the organization, professionals from almost every country and territory across the globe—including nearly 15% of the world's ophthalmologists—have trained on the platform.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

The microRNA(miR)-17-92 cluster is known to play an important role in cell signaling, but its specific functions in the eye are not well understood. The researchers’ focus lies in gaining insights into the mechanisms of miR-17-92 cluster members and their effects on IOP.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

Nebraska Medicine taps technology for use in clinics.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The study helped identify predisposing factors for severe SANS in astronauts.

According to the company, its ViaLase Laser combines state-of-the-art femtosecond laser technology with micron-level image guidance to deliver the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT), marking a shift in glaucoma care.

iStent implantations increased sharply, whereas trabeculectomies saw a decline.

Lens feathering resulting from intraocular gas can interfere with the visualization needed to perform posterior segment surgery

The trial will evaluate VRDN-001, an intravenously delivered monoclonal antibody that acts as a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R).

The retrospective study was conducted at King Khaled Eye Specialist Hospital (KKESH), in Riyadh, Saudi Arabia, to review the impact of the COVID-19 pandemic on the training program by comparing the years 2018 and 2019 before the pandemic to 2020 and 2021 after the pandemic.

Sherman practiced in New York for more than 50 years and was the founder of Manhattan Ophthalmology Associates.

Sruthi Arepalli, MD, spoke about her presentation, "Assessing retinal vascular changes in Alzheimer's disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.

According to Allgenesis Biotherapeutics, AG-8030 is a first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop for the treatment of DED.

Yasha Modi, MD, spoke about the DAVIO phase 2 trial and the upcoming LUGANO phase 3 trial at the annual ASRS meeting in Stockholm, Sweden.

CVD may interfere with an eye care provider’s ability to differentiate between choroidal melanoma and choroidal nevus

Nikoloz Labauri, MD, FVRS, founder of DAVINCI Eye Clinic in Tbilisi, Georgia, discusses his presentation, "Suspensory Macular Buckling for Myopic Traction Maculopathy" at this year's American Society of Retina Specialists (ASRS) meeting in Stockholm, Sweden